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In patients with nonvalvular atrial fibrillation (AF), the risk of stroke varies considerably according to individual clinical status. The 
CHA2DS2-VASc score is better than the CHADS2 score for identifying truly lower risk patients with AF. With the advent of novel oral anti-
coagulants (NOACs), the strategy for antithrombotic therapy has undergone significant changes due to its superior efficacy, safety and 
convenience compared with warfarin. Furthermore, new aspects of antithrombotic therapy and risk assessment of stroke have been re-
vealed: the efficacy of stroke prevention with aspirin is weak, while the risk of major bleeding is not significantly different from that of 
oral anticoagulant (OAC) therapy, especially in the elderly. Reflecting these pivotal aspects, previous guidelines have been updated in re-
cent years by overseas societies and associations. The Korean Heart Rhythm Society has summarized the new evidence and updated rec-
ommendations for stroke prevention of patients with nonvalvular AF. First of all, antithrombotic therapy must be considered carefully and 
incorporate the clinical characteristics and circumstances of each individual patient, especially with regards to balancing the benefits of 
stroke prevention with the risk of bleeding, recommending the CHA2DS2-VASc score rather than the CHADS2 score for assessing the risk 
of stroke, and employing the HAS-BLED score to validate bleeding risk. In patients with truly low risk (lone AF, CHA2DS2-VASc score of 0), 
no antithrombotic therapy is recommended, whereas OAC therapy, including warfarin (international normalized ratio 2–3) or NOACs, is 
recommended for patients with a CHA2DS2-VASc score ≥2 unless contraindicated. In patients with a CHA2DS2-VASc score of 1, OAC ther-
apy should be preferentially considered, but depending on bleeding risk or patient preferences, antiplatelet therapy or no therapy could 
be permitted. (Korean Circ J 2015;45(1):9-19)
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Introduction
The prevalence of atrial fibrillation (AF) is approximately 1.5–2% 
of the general population in the developed world, with a tendency 
to increase abruptly with age, and is estimated to be about 10% of 
the population over 80 years old. AF is accompanied by a five-fold 
risk of stroke and a three-fold incidence of congestive heart failure, 
as well as higher mortality.1) Especially in patients with AF, stroke 
has a tendency to involve a larger territory, with brain infarction 
that results in more severe neurological disability than that by other 
causes. Hence, the importance of antithrombotic therapy on AF has 
been consistently emphasized.2) 
Since 2003, pivotal results from randomized controlled trials have 
been sequentially released that detail the efficacy and safety of 
novel oral anticoagulants (NOACs) for the prevention of stroke in 
nonvalvular AF patients. Compared with conventional antithrom-
botics such as aspirin, clopidogrel or warfarin, NOACs have differ-
ent action mechanisms that are classified into two classes: oral di-
rect thrombin inhibitor (ximelagatran, dabigatran) and oral direct 
factor Xa inhibitor (rivaroxaban, apixaban, edoxaban).3-8) While ximel-
agatran was developed first and withdrawn in the middle of a clini-
cal application due to severe liver toxicity, other NOACs developed 
afterward have had favorable risk-benefit profiles with non-inferi-
or or superior reductions in stroke, intracranial hemorrhage (ICH), 
and mortality, and with similar incidence of major bleeding as war-
farin. Due to these findings, NOACs have been recommended as 
anticoagulant therapy for nonvalvular AF patients in the updated 
guidelines of Asian and Western societies since 2010. 
The authors have reviewed guidelines issued in recent years by 
Asian, European, and North American societies and organizations, 
and based on these guidelines, provide updated recommendations 
for the prevention of stroke in nonvavular AF patients.
Previous Recommendations for Antithrombotic 
Therapies in Korea
In Korea, the clinical guideline for the prevention of stroke in pa-
tients with AF was published in 2009, even before the introduction 
of NOACs in clinical practice. The summary of antithrombotic thera-
pies for the prevention of stroke in nonvalvular AF patients was as 
follows:9)
1) Antithrombotic therapy (warfarin or aspirin) was recommended 
to prevent stroke in patients with nonvalvular AF according to as-
sessment of their absolute stroke risk, estimated bleeding risk, pa-
tient preferences, and access to high-quality anticoagulation moni-
toring. 
2) Warfarin {international normalized ratio (INR) 2.0 to 3.0} was 
recommended for high-risk (4% annual risk of stroke) patients (and 
most moderate-risk patients according to an assessment of bleed-
ing risk) with AF who had no clinically significant contraindications 
to oral anticoagulants (OACs).
3) Although not yet established by randomized studies, in patients 
over 75 years of age, warfarin (INR 2.0 to 3.0) may be used for the 
primary prevention of stroke in patients with AF.
Thereafter, due to the excellent anticoagulant efficacy of NOACs 
for nonvalvular AF patients and the revision of overseas recommen-
dations, an update was issued in 2012 on the primary prevention of 
stroke in AF patients by the Korean Stroke Society.2)
However, in real clinical practice, aspirin is preferred for patients 
with low-risk of stroke, and overused for nonvavular AF patients 
without risk factors (lone AF, CHA2DS2-VASc score of 0) that obvi-
ously gain no benefit from antithrombotic therapy. On the other 
hand, despite the superior efficacy in stroke prevention compare 
to antiplatelets such as aspirin or clopidogrel, anticoagulation with 
warfarin (oral vitamin K antagonist) is inadequately underused be-
cause of low compliance owing to frequent INR tests, concern about 
severe bleeding complications, and INR fluctuations due to interac-
tion with concomitant medications, food, or herbal medicine. 
Recently Updated Overseas Recommendation and 
Evidences
Stroke and bleeding risk assessment with antithrombotic 
therapy in nonvalvular atrial fibrillation patients
The CHADS2 score, expressed as an acronym, has been widely used 
to evaluate the risk of stroke in AF patients and assigns a single 
point for several factors, namely, Congestive Heart Failure, Hyperten-
sion, Age (over 75 years old) and Diabetes Mellitus, and two points 
for Stroke or transient ischemic attack (TIA). However, it has been 
found to have a limitation with discriminating “ruly low-risk” pa-
tients from low-risk (CHADS2 score=0) patients that have no need 
for antithrombotic therapy. To overcome this issue, the European 
Society of Cardiology (ESC) 2010 guideline introduced the CHA2DS2-
VASc score, which incorporates additional weights for age (2 points 
for age over 75 year old, 1 point for 65–74), gender (1 point for fe-
male) and vascular disease (1 point) (Table 1).10) Thereafter, the Ca-
nadian Cardiovascular Society (CCS) AF 2012 guideline, APHRS 2013 
guideline, and American Heart Association (AHA)/American College 
of Cardiology (ACC)/Heart Rhythm Society (HRS) 2014 guideline 
were revised to prefer the CHA2DS2-VASc score for evaluating the 
risk of stroke or to adopt CHA2DS2-VASc score instead of the CHADS2 
score.11-13) However, antithrombotic therapy is not recommended for 
female patients with no other risk factors of stroke. 
In previous recommendations, a CHADS2 score of 1 was the decisive 
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factor for implementing antithrombotic therapy. Accumulating ev-
idence suggest that the CHA2DS2-VASc score is better at identifying 
“truly low-risk” patients in AF, and is as good as or possibly better 
than the CHADS2 score in predicting patients who will develop 
stroke and thromboembolism.14) Hence the CHA2DS2-VASc score 
should be adopted in Korea to avoid unnecessary antithrombotic 
therapy among low-risk patients, and to more precisely refine the 
risk of stroke in AF patients.
Antithrombotic therapy for stroke prevention should be con-
cerned with balancing the risk of stroke against the risk of major 
bleeding such as ICH, the most dangerous complication, and severe 
bleeding that require more than 2 pints of transfusion. Generally, 
the risk of bleeding is proportionally increased with antithrombotic 
intensity in the following order: 1) aspirin (75–325 mg/day) or 
clopidogrel (75 mg/day), 2) a combination of aspirin and clopido-
grel, and 3) low dose dabigatran (110 mg bid.), 4) high dose dabig-
atran (150 mg bid.), rivaroxaban, apixaban and warfarin (INR: 2–3), 
which carry similar risks.11)
The ESC 2010 and CCS AF 2012 guidelines recommended the use 
of HAS-BLED bleeding risk score for the evaluation of bleeding risk 
in clinical practice (Table 2). The HAS-BLED bleeding risk score con-
siders the following as bleeding risk factors; Hypertension, Abnormal 
renal/liver function, Stroke, Bleeding history or predisposition, La-
bile INRs, Elderly (over 65 years old), and Drug/alcohol. According to 
this score system, the risk of major bleeding with a HAS-BLED score 
of 0–1 is about 1%, and about 12.5% annually with a HAS-BLED 
score of 5.15) In patients with a HAS-BLED score of 3, the risk of ma-
jor bleeding is about 3.74% and coincides with a high-risk of stroke 
in AF patients. Therefore, to minimize bleeding complications, vigi-
lant caution and regular review are essential, as well as efforts to 
correct potentially reversible risk factors for bleeding in patients with 
HAS-BLED score ≥3. A high HAS-BLED score per se should not ex-
clude patients from OAC therapy. NOACs can be recommended for 
patients with labile INRs because of its predictable effect without 
INR monitoring, and fewer food and drug interactions. Hyperten-
sion, previous stroke, TIA and old age, which are known as risk fac-
tors for stroke, overlap with the risk factors for concomitant bleed-
ing. In daily clinical practice, caution should be taken because 
bleeding risk is often enhanced proportionally with increases in the 
CHA2DS2-VASc score.
Pivotal clinical trials using novel oral anticoagulants
Dabigatran versus Warfarin: The Randomized Evaluation of 
Long-Term Anticoagulation Therapy (RE-LY) 4)
The RE-LY clinical trial was a prospective, randomized, open-la-
bel, phase III trial comparing two blinded doses of dabigatran etex-
ilte {110 mg bid (D110) or 150 mg bid (D150)} with adjusted-dose 
warfarin (INR 2.0–3.0), in which the primary outcome was stroke or 
systemic embolism. Primary outcome rates were 1.69% per year in 
the warfarin group, as compared with 1.53% per year in the D110 
group {relative risk (RR), 0.91; 95% CI, 0.74 to 1.11; p<0.001 for non-
inferiority} and 1.11% per year in the D150 group {RR, 0.66; 95% 
confidence interval (CI), 0.53 to 0.82; p<0.001 for superiority}. The 
rate of major bleeding was 3.36% per year in the warfarin group, 
as compared with 2.71% per year in the D110 group (p=0.003) and 
3.11% per year in the D150 group (p=0.31). The rate of hemorrhagic 
stroke was 0.38% per year in the warfarin group, as compared with 
0.12% per year with the D110 group (p<0.001) and 0.10% per year 
Table 1. The CHA2DS2-VASc score
Letter Risk factor Score
C Congestive heart failure/LV dysfunction 1
H Hypertension 1
A2 Age ≥75 2
D Diabetes mellitus 1
S2 Stroke/TIA/thrombo-embolism 2
V Vascular disease* 1
A Age 65–74 1
S Sex category (i.e., female sex) 1
Maximum score 9
Congestive heart failure/LV dysfunction means LV ejection fraction ≤40%. 
Hypertension includes the patients with current antihypertensive medica-
tion. *Prior myocardial infarction, peripheral artery disease, aortic plaque. 
LV: left ventricular, TIA: transient ischemic attack
Table 2. The HAS-BLED bleeding risk score
Letter Risk factor Score
H Hypertension 1
A Abnormal renal and liver function (1 points each) 1 or 2
S Stroke 1
B Bleeding 1
L Labile INRs 1
E Elderly (e.g., age >65 years) 1
D Drugs or alcohol (1 point each) 1 or 2
Maximum score 9
Hypertension means systolic blood pressure >160 mm Hg. Abnormal renal 
function means the presence of chronic dialysis or renal transplantation or 
serum creatinine ≥200 µmol/L (about 2.262 mg/dL: 88.4 µmol/L=1.0 mg/dL). 
Abnormal liver function means chronic hepatic disease or biochemical evi-
dence of significant liver dysfunction (e.g., bilirubin >two times of upper limit 
of normal, in association with aspartate aminotransferase/alanine amino-
transferase/alkaline phosphatase >three times of upper limit normal, etc.). 
Bleeding means previous bleeding history and/or predisposition to bleeding, 
e.g., bleeding diathesis, anemia, etc. Labile INRs means unstable/high INRs or 
poor time in therapeutic range (e.g., <60%). Drugs/alcohol use means con-
comitant use of drugs, such as antiplatelet agents, nonsteroidal anti-in-
flammatory drugs, or alcohol abuse, etc. INR: international normalized ratio
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with the D150 group (p<0.001). The mortality rate was 4.13% per 
year in the warfarin group, as compared with 3.75% per year with 
the D110 group (p=0.13) and 3.64% per year with the D150 group 
(p=0.051). Rates of hemorrhagic stroke and ICH were lower with 
both doses of dabigatran, but gastrointestinal bleeding was signifi-
cantly higher in the D150 group.  
In patients with AF, D110 was associated with rates of stroke and 
systemic embolism similar to those associated with warfarin, as well 
as lower rates of major hemorrhage. D150, as compared with warfa-
rin, was associated with lower rates of stroke and systemic embo-
lism but similar rates of major hemorrhage.
Rivaroxaban versus Warfarin: Rivaroxaban Once Daily Oral Direct 
Factor Xa Inhibition Compared with Vitamin K Antagonism for the 
Prevention of Stroke and Embolism Trial in Atrial Fibrillation 
(ROCKET AF) 5)
The ROCKET AF clinical trial was a randomized, double-blind and 
double-dummy trial for either rivaroxaban 20 mg taken daily (15 mg 
daily for those with estimated creatinine clearance 30–49 mL/min) 
or dose-adjusted warfarin for patients with nonvalvular AF who were 
at considerably higher risk of stroke than those in other NOAC AF 
trials. The mean time in the therapeutic range (TTR) was 55%, which 
was lower than in other randomized trials. The primary end point, 
stroke or systemic embolism, occurred in 188 patients in the rivar-
oxaban group (1.7% per year) and in 241 in the warfarin group (2.2% 
per year) {hazard ratio (HR), 0.79; 95% CI, 0.66 to 0.96; p<0.001 for 
noninferiority}. In the intention-to-treat analysis, the primary end 
point occurred in 269 patients in the rivaroxaban group (2.1% per 
year) and in 306 patients in the warfarin group (2.4% per year) (HR, 
0.88; 95% CI, 0.74 to 1.03; p<0.001 for noninferiority; p=0.12 for 
superiority). Major and nonmajor clinically relevant bleeding oc-
curred in 1475 patients in the rivaroxaban group (14.9% per year) 
and in 1449 in the warfarin group (14.5% per year) (HR, 1.03; 95% 
CI, 0.96 to 1.11; p=0.44), with significantly lower ICH (0.5% vs. 0.7%, 
p=0.02) and fatal bleeding (0.2% vs. 0.5%, p=0.003) in the rivarox-
aban group. However, GI bleeding was higher in the rivaroxaban 
group than in the warfarin group (3.3% vs. 2.2%, p<0.001).
In patients with AF, rivaroxaban was noninferior to warfarin for 
the prevention of stroke or systemic embolism. There was no sig-
nificant difference between groups in the risk for major bleeding, 
although intracranial and fatal bleeding occurred less frequently in 
the rivaroxaban group. 
Apixaban versus Aspirin: Apixaban versus Acetylsalicylic Acid to 
Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or 
Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) 6)
The AVERROES clinical trial was a randomized, double-blind and 
double-dummy trial with AF patients who were unsuitable candi-
dates for warfarin, comparing the efficacy of apixaban to that of as-
pirin for the prevention of stroke or systemic embolism. There were 
51 primary outcome events (1.6% per year) in the apixaban group 
and 113 (3.7% per year) in the aspirin group (HR, 0.45; 95% CI, 0.32 
to 0.62; p<0.001). The mortality was 3.5% per year in the apixaban 
group and 4.4% per year in the aspirin group (HR, 0.79; 95% CI, 0.62 
to 1.02; p=0.07). There were 44 cases of major bleeding (1.4% per 
year) in the apixaban group and 39 (1.2% per year) in the aspirin 
group (HR, 1.13; 95% CI, 0.74 to 1.75; p=0.57). Intracranial bleed-
ing occurred in 11 cases with apixaban and 13 with aspirin. Apixa-
ban reduced the risk of a first hospitalization for cardiovascular 
causes compared with aspirin (12.6% per year vs. 15.9% per year, 
p<0.001). 
In patients with AF for whom vitamin K antagonist therapy was 
unsuitable, apixaban reduced the risk of stroke or systemic embolism 
without significantly increasing the risk of major bleeding or ICH.
Apixaban versus Warfarin: Apixaban for Reduction in Stroke and 
Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) 7)
The ARISTOTLE clinical trial was a randomized, double-blind, dou-
ble-dummy, phase III trial comparing apixaban (5 mg twice daily, 
or a dose adjustment to 2.5 mg twice daily in patients who met 
two of the following factors: ≥80 years, weight ≤60 kg or a serum 
creatinine ≥1.5 mg/dL) with dose-adjusted warfarin (INR 2.0–3.0) 
in patients with nonvalvular AF. The primary outcome was ischemic 
or hemorrhagic stroke or systemic embolism. The rate of primary 
outcome was 1.27% per year in the apixaban group, as compared 
with 1.60% per year in the warfarin group (HR, 0.79; 95% CI, 0.66 
to 0.95; p<0.001 for noninferiority; p=0.01 for superiority). The rate 
of major bleeding was 2.13% per year in the apixaban group, as 
compared with 3.09% per year in the warfarin group (HR, 0.69; 95% 
CI, 0.60 to 0.80; p<0.001), and the mortality from any cause was 
3.52% and 3.94%, respectively (HR, 0.89; 95% CI, 0.80 to 0.99; p= 
0.047). The rate of hemorrhagic stroke was 0.24% per year in the 
apixaban group, as compared with 0.47% per year in the warfarin 
group (HR, 0.51; 95% CI, 0.35 to 0.75; p<0.001), and the rate of isch-
emic or uncertain type of stroke was 0.97% per year in the apixaban 
group and 1.05% per year in the warfarin group (HR, 0.92; 95% CI, 
0.74 to 1.13; p=0.42). In patients with AF, apixaban was superior to 
warfarin in preventing stroke or systemic embolism, caused less 
bleeding, and resulted in lower mortality.
Edoxaban versus Warfarin: The Effective Anticoagulation with 
Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in 
Myocardial Infarction 48 (ENGAGE AF-TIMI 48) 8)
The ENGAGE AF-TIMI 48 clinical trial was a randomized, double-
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blind, double-dummy trial comparing two once-daily regimens of 
edoxaban {high dose: 60 mg/day (E60), low dose: 30 mg/day (E30)} 
with warfarin. The primary end point was stroke or systemic embo-
lism in patients with moderate to high risk AF. The annualized rate 
of the primary end point was 1.50% with warfarin, as compared 
with 1.18% with E60 (HR, 0.79; 97.5% CI, 0.63 to 0.99; p<0.001 for 
noninferiority) and 1.61% with E30 (HR, 1.07; 97.5% CI, 0.87 to 
1.31; p=0.005 for noninferiority). In the intention-to-treat analysis, 
there was a trend favoring E60 versus warfarin (HR, 0.87; 97.5% 
CI, 0.73 to 1.04; p=0.08) and an unfavorable trend with E30 versus 
warfarin (HR, 1.13; 97.5% CI, 0.96 to 1.34; p=0.10). The rate of ma-
jor bleeding was 3.43% per year with warfarin versus 2.75% per 
year with E60 (HR, 0.80; 95% CI, 0.71 to 0.91; p<0.001) and 1.61% 
with E30 (HR, 0.47; 95% CI, 0.41 to 0.55; p<0.001). The correspond-
ing annual mortality from cardiovascular causes were 3.17% versus 
2.74% (warfarin vs. E30; HR, 0.86; 95% CI, 0.77 to 0.97; p=0.01), and 
2.71% (warfarin vs. E60; HR, 0.85; 95% CI, 0.76 to 0.96; p=0.008). 
The corresponding rates of the key secondary end point (a compos-
ite of stroke, systemic embolism, or death from cardiovascular 
causes) were 4.43% versus 3.85% (warfarin vs. E30; HR, 0.87; 95% 
CI, 0.78 to 0.96; p=0.005), and 4.23% (warfarin vs. E60; HR, 0.95; 
95% CI, 0.86 to 1.05; p=0.32).
Both once-daily regimens of edoxaban were noninferior to warfa-
rin with respect to the prevention of stroke or systemic embolism, 
and were associated with significantly lower rates of bleeding and 
death from cardiovascular causes.
The summary of clinical trials with NOACs is as follows: in the 
prevention of stroke, NOACs are superior or noninferior to warfarin 
therapy with well controlled INR, and show similar or lower inci-
dence of bleeding complications.16) Therefore NOACs can be recom-
mended for patients with uncontrolled labile INRs, history of bleed-
ing complications or previous stroke for whom warfarin was previously 
prescribed for prevention.17) 
Antiplatelet therapy in atrial fibrillation patients unsuitable 
for oral vitamin K antagonist therapy 
Effect of Clopidogrel Added to Aspirin in Patients with Atrial 
Fibrillation: The Atrial Fibrillation Clopidogrel Trial with Irbesartan 
for Prevention of Vascular Events (ACTIVE A) 18)
The ACTIVE A clinical trial compared the efficacy of aspirin mono-
therapy (75–100 mg/day) to that of combination therapy involving 
aspirin and clopidogrel (75 mg/day) in AF patients unsuitable for 
warfarin therapy with more than one risk factor for stroke. The pri-
mary outcome was the composite of stroke, myocardial infarction, 
non-central nervous system systemic embolism, or death from vas-
cular causes. Major vascular events occurred in 832 patients with 
combination therapy (6.8% per year) and in 924 patients with mono-
therapy (7.6% per year) (RR, 0.89; 95% CI, 0.81 to 0.98; p=0.01). 
The difference was primarily due to a reduction in the rate of stroke 
with combination therapy. Stroke occurred in 296 patients with 
combination therapy (2.4% per year) and 408 patients with mono-
therapy (3.3% per year) (RR, 0.72; 95% CI, 0.62 to 0.83; p<0.001). 
Myocardial infarction occurred in 90 patients with combination 
therapy (0.7% per year) and in 115 with monotherapy (0.9% per 
year) (RR, 0.78; 95% CI, 0.59 to 1.03; p=0.08). Major bleeding oc-
curred in 251 patients with combination therapy (2.0% per year) and 
in 162 patients with monotherapy (1.3% per year) (RR, 1.57; 95% 
CI, 1.29 to 1.92; p<0.001).
In patients with AF for whom vitamin K antagonist therapy was 
unsuitable, the addition of clopidogrel to aspirin reduced the risk of 
major vascular events, especially stroke, and increased the risk of 
major hemorrhage.
Clopidogrel Plus Aspirin versus Oral Anticoagulation for Atrial 
Fibrillation in the Atrial Fibrillation Clopidogrel Trial with 
Irbesartan for Prevention of Vascular Events (ACTIVE W): 
a randomized controlled trial 19)
The ACTIVE W was a randomized, controlled, open-label trial com-
paring the efficacy of combination therapy (aspirin 75–100 mg/day 
and clopidogrel 75 mg/day) to that of oral vitamin K antagonist 
(warfarin) therapy. The study was terminated early because of clear 
evidence of the superiority of warfarin therapy. There were 165 pri-
mary events in patients on warfarin therapy (annual risk 3.93%) and 
234 in those on combination therapy (annual risk 5.60%; RR 1.44; 
95% CI, 1.18 to 1.76; p=0.0003). 
Warfarin therapy was superior to the combination therapy for 
prevention of vascular events in patients with AF at high risk of 
stroke, especially in those already taking oral anticoagulation therapy.
In a meta-analysis of sixteen trials, adjusted-dose warfarin showed 
a remarkable reduction of stroke in AF patients by 62% whereas as-
pirin reduced the risk of stroke by 22%, although major extracranial 
bleeding was increased by warfarin therapy.20) Compared with as-
pirin, warfarin significantly decreased the risk of all strokes, includ-
ing ischemic strokes, and cardiovascular events for patients re-
gardless of AF type.21) While advanced age (>75 years) is considered 
a clear risk factor for both stroke and bleeding, anticoagulant thera-
py should be regarded as the first-line of therapy rather than aspi-
rin.22) However, in real clinical practice, antiplatelet agents are ap-
plied as alternatives when OAC therapy is unsuitable. Based on the 
results of the ACTIVE A trial, even with cases where it is hard to de-
cide whether aspirin monotherapy and combination therapy is 
more beneficial, combination therapy should be considered when 
the risk of bleeding is low. 
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The Recommendation of Korean Heart Rhythm 
Society for Patients with Nonvalvular Atrial 
Fibrillation (Table 3)
1.  Antithrombotic therapy selection should be considered using 
the same criteria, irrespective of the pattern of AF such as par-
oxysmal, persistent, and permanent.
2.  The CHA2DS2-VASc score is recommended for the assessment 
of stroke risk.
2-1.  The CHA2DS2-VASc score should be used for appropriate 
antithrombotic therapy.
2-2.  NOACs or anticoagulant therapy using warfarin should 
be recommended for antithrombotic therapy when the 
CHA2DS2-VASc score is 1 or greater.
2-3.  Antithrombotic therapy is not recommended when the 
CHA2 DS2-VASc score is 0.
2-4.  The CHA2DS2-VASc score is considered as 0 when being fe-
male is the only risk factor.
In the ESC 2012 guideline, NOACs are preferably recommended 
over warfarin for patients with a score of 1 or greater, while no anti-
thrombotic therapy is recommended for patients with a score of 0. 
In the APHRS 2013 guideline, NOACs or warfarin are recommend-
ed impartially for patients with a score ≥2. NOACs (dabigatrin or 
apixaban, excluding rivaroxaban) are preferably recommended for 
patients with a score of 1, whereas rivaroxaban or warfarin are con-
sidered as alternatives. No antithrombotic therapy is recommended 
for patients with a score of 0. In the ROCKET AF clinical trial, rivarox-
aban was administered to patients with CHADS2 score of 2 or great-
er. Hence, it is recommended as an alternative when the CHA2DS2-
VASc score is 1 (APHRS 2013). Meanwhile, in the 2014 AHA/ACC/
HRS guideline, the strategy for antithrombotic therapy for patients 
with CHA2DS2-VASc score of 1 seems to be diverse: no antithrom-
botic therapy or treatment with OAC or aspirin can be considered. 
3. Warfarin is recommended in the following cases:
3-1.  Patients with valve replacement or rheumatic valve dis-
ease.
3-2.  Patients with nonvalvular AF in whom INR is well con-
trolled and no significant bleeding is present.
4. Optimal INR during warfarin treatment
4-1. Optimal INR range is 2–3.
4-2.  Time in therapeutic range should be at least over 60% to 
maximize to the benefit of warfarin
In the APHRS 2013 guideline, the optimum range of INR is con-
sidered to be 1.6–2.6 in Asian elderly (≥70 years old) to minimize ce-
rebral hemorrhage and other severe bleeding complications as well 
as to effectively prevent ischemic stroke.
5.  Aspirin monotherapy or combination therapy with aspirin and 
clopidogrel can be considered when oral anticoagulation 
therapy is not suitable or patients refuse the use of OACs.
6.  Oral anticoagulation therapy may be judiciously combined 
with antiplatelet therapy in the following cases:
6-1.  Recurrence of thromboembolism despite adequate oral 
anticoagulation therapy.
6-2.  Concomitant antiplatelet therapy may be considered for 
the treatment of nonembolic cerebral infarction or TIA. 
6-3. Presence of concomitant ischemic heart disease.
6-4. Coronary artery stenting.
7.  Switch from warfarin to NOACs, and cautions for the admin-
istration of NOACs.
7-1.  NOACs may not be used in place of warfarin in patients 
with stable anticoagulation control without bleeding com-
plications.
7-2.  NOACs are recommended instead of warfarin for patients 
requiring anticoagulation therapy who have hypersensi-
tivity or contraindication against warfarin, cannot maintain 
an INR within the optimal range, or have cerebral hemor-
rhage despite adequate INR maintainance. 
7-3.  For the administration of dabigatran, 150 mg twice daily 
is recommended as a standard regimen. Dose reduction (110 
mg twice daily) should be considered in the following 
cases:
  - Elderly patients (≥80 years old), concomitant adminis-
tration of interacting drugs (e.g., verapamil), high bleed-
ing risk (HAS-BLED score ≥3), or moderate renal dysfunc-
tion (CrCl 30–49 mL/min).
7-4.  For the administration of rivaroxaban, 20 mg once daily is 
recommended as a standard regimen. Dose reduction (15 mg 
once daily) should be considered in the following cases:
  - High bleeding risk (HAS-BLED score ≥3) or moderate renal 
dysfunction (CrCl 30–49 mL/min).
7-5.  For the administration of apixaban, 5 mg twice daily is rec-
ommended as a standard regimen. Dose reduction (2.5 mg 
twice daily) should be considered for the following cases:
 - Renal dysfunction (CrCl 30–49 mL/min)
  - Patients who have 2 or more of the following 3 factors: 
  Elderly patients (≥80 years old), body weight ≤60 kg, or  
 serum creatinine level ≥1.5 mg/dL.
7-6.  Assessment of renal function should be carried out prior 
to the use of NOACs and annually monitored in patients 
with normal (CrCl ≥80 mL/min) or mild renal dysfunction 
(CrCl 50–79 mL/min). It should be monitored 2–3 times 
per year in patients with moderate renal dysfunction 
(CrCl 30–49 mL/min).
7-7.  NOACs are not recommended for patients with severe 
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Table 3. The recommendation of the Korean Heart Rhythm Society for patients with nonvalvular AF 
1.  The selection of antithrombotic therapy should be considered using the same criteria irrespective of the pattern of AF such as paroxysmal, persistent, 
and permanent.
2.  The CHA2DS2-VASc score is recommended for the assessment of stroke risk.
  2-1. The CHA2DS2-VASc score should be used for the appropriate antithrombotic therapy.
 2-2. NOACs or anticoagulant therapy using warfarin should be recommended for antithrombotic therapy when the CHA2DS2-VASc score is 1 or greater.
  2-3. Antithrombotic therapy is not recommended when the CHA2DS2-VASc score is 0.
  2-4. The CHA2DS2-VASc score is considered as 0 when being female is the only risk factor.
3.  Warfarin is recommended in the following cases:
 3-1. Patients with valve replacement or rheumatic valve disease.
  3-2. Patients with nonvalvular AF in whom INR is well controlled and no significant bleeding is present.
4.  Optimal INR during warfarin treatment
  4-1. Optimal INR range is 2–3.
  4-2. Time in therapeutic range should be at least over 60% to maximize the benefit of warfarin.
5.  Aspirin monotherapy or combination therapy with aspirin and clopidogrel can be considered when oral anticoagulation therapy is not suitable or 
patients refuse the use of oral anticoagulants.
6.  Oral anticoagulation therapy may be judiciously combined with antiplatelet therapy in the following cases:
  6-1. Recurrence of thromboembolism despite adequate oral anticoagulation therapy.
  6-2. Concomitant antiplatelet therapy may be considered for the treatment of nonembolic cerebral infarction or TIA. 
  6-3. Presence of concomitant ischemic heart disease.
  6-4. Coronary artery stenting.
7.  Switch from warfarin to NOACs, and cautions for the administration of NOACs.
  7-1. NOACs may not be used in place of warfarin in patients with stable anticoagulation control without bleeding complications.
  7-2.  NOACs are recommended in place of warfarin for patients requiring anticoagulation therapy who have hypersensitivity or contraindication against  
 warfarin, cannot maintain an INR within the optimal range, or have cerebral hemorrhage despite an INR that is adequately maintained. 
  7-3.  For the administration of dabigatran, 150 mg twice daily is recommended as a standard regimen. Dose reduction (110 mg twice daily) should be  
 considered in the following cases: 
- Elderly patients (≥80 years old), concomitant administration of interacting drugs (e.g., verapamil), high bleeding risk (HAS-BLED score ≥3), or  
   moderate renal dysfunction (CrCl 30–49 mL/min).
  7-4.  For the administration of rivaroxaban, 20 mg once daily is recommended as a standard regimen. Dose reduction (15 mg once daily) should be  
 considered in the following cases: 
 - High bleeding risk (HAS-BLED score ≥3) or moderate renal dysfunction (CrCl 30–49 mL/min).
  7-5.  For the administration of apixaban, 5 mg twice daily is recommended as a standard regimen. Dose reduction (2.5 mg twice daily) should be  
 considered for the following cases: 
 - Renal dysfunction (CrCl 30–49 mL/min) 
 - Patients who have 2 or more of the following 3 factors: 
 Elderly patients (≥80 years old), body weight ≤60 kg, or serum creatinine level ≥1.5 mg/dL.
  7-6.  The assessment of renal function should be carried out prior to the use of NOACs and annually monitored in patients with normal (CrCl ≥80 mL/min) 
 or mild renal dysfunction (CrCl 50–79 mL/min). It should be monitored 2–3 times per year in patients with moderate renal dysfunction (CrCl 30–49  
 mL/min).
  7-7. NOACs are not recommended in patients with severe renal dysfunction (CrCl <30 mL/min).
8.  Anticoagulant therapy for patients who are scheduled for an invasive procedure or a surgery with the possibility of bleeding complications.
  8-1.  For patients with warfarin therapy, INR should be measured within 24 hours before an invasive procedure or a surgery, and an INR of ≤1.5 is  
 generally considered safe with regard to the risk of periprocedural or perioperative bleeding. Warfarin can be reintroduced 24 hours later when  
 hemostasis is confirmed and the patient is under a stable condition. 
  8-2.  For patients with CrCl ≥50 mL/min, dabigatran should be ceased 1 day prior to procedures with low bleeding risk, and 2–3 days for high bleeding  
 risk procedures. For patients with CrCl 30–49 mL/min, dabigatran should be ceased 2 days prior to procedures with low bleeding risk, and 3–4 days  
 prior to procedures with high bleeding risk.
  8-3.  For patients with CrCl ≥30 mL/min, rivaroxaban should be ceased 1 day prior to procedures with low bleeding risk, and 2 days prior to procedures  
 with high bleeding risk. For patients with <30 mL/min, ribaroxaban should be ceased 2 days prior to procedures with low bleeding risk, and more  
 than 2 days prior to procedures with high bleeding risk.
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renal dysfunction (CrCl <30 mL/min).
8. Anticoagulant therapy for patients scheduled for an invasive 
procedure or surgery with the possibility of bleeding complications.
8-1.  For patients on warfarin therapy, INR should be measured 
within 24 hours before an invasive procedure or a surgery, 
and an INR of ≤1.5 is generally considered safe with re-
gard to the risk of periprocedural or perioperative bleed-
ing. Warfarin can be reintroduced 24 hours later when 
hemostasis is confirmed and the patient is under a stable 
condition. 
8-2.  For patients with CrCl ≥50 mL/min, dabigatran should be 
ceased 1 day prior to procedures with low bleeding risk, 
and 2–3 days for high bleeding risk procedures. For patients 
with CrCl 30–49 mL/min, dabigatran should be ceased 2 
days prior to procedures with low bleeding risk, and 3–4 
days for high bleeding risk procedures.
8-3.  For patients with CrCl ≥30 mL/min, rivaroxaban should 
be ceased 1 day prior to procedures with low bleeding risk, 
and 2 days prior to procedures with high bleeding risk. 
For patients with <30 mL/min, ribaroxaban should be 
ceased 2 days prior to procedures with low bleeding risk, 
and more than 2 days prior to procedures with high bleed-
ing risk.
8-4.  For patients with CrCl ≥30 mL/min, apixaban should be 
ceased 1 day prior to procedures with low bleeding risk, 
and 2 days prior to procedures with high bleeding risk. For 
patients with <30 mL/min, apixaban should be ceased 2 
days prior to procedures with low bleeding risk, and more 
than 2 days prior to procedures with high bleeding risk.
During the administration of warfarin, bridge therapy can be con-
sidered for patients with high risk of thromboembolism. However, 
bridge therapy is not required with NOACs. Caution should be taken 
with NOACs, because there is no appropriate antagonist.
9. Anticoagulation therapy for conducting an elective cardiover-
sion or radiofrequency catheter ablation
9-1.  To conduct elective direct current cardioversion for pa-
tients with AF of ≥48 hours duration or unknown time of 
occurrence, anticoagulant therapy with warfarin (INR 2.0–
3.0) is recommended for ≥3 weeks prior to and ≥4 weeks 
after cardioversion to reduce the risk of thromboembolism. 
9-2.  To conduct radiofrequency catheter ablation for patients 
with AF of ≥48 hours duration or unknown time of occur-
rence, anticoagulant therapy with warfarin (INR 2.0–3.0) 
is recommended for ≥3 weeks prior to and 2 months af-
ter cardioversion to reduce the risk of thromboembolism. 
9-3.  For the application of NOACs prior to or after elective car-
dioversion, supporting evidence is insufficient and limited. 
In the subgroup analysis of the RE-LY trial with dabigatran, the 
incidence of thromboembolism did not increase in the first 30 days 
after defibrillation, compared to the incidence with warfarin. Cur-
rently, several studies investigating this issue are being conducted 
with NOACs, and the recommendation may be amended according 
to the study results. 
10. For patients with atrial flutter, antithrombotic therapy is rec-
ommended according to the same criteria applied for AF.
The Characteristics in Stroke and Bleeding  
Complications When Treating with Warfarin or 
Novel Oral Anticoagulants in Asian Population: 
Ethnic Difference
Dabigatran versus Warfarin: Effects on Ischemic and  
Hemorrhagic Strokes and Bleeding in Asians and Non-Asians 
with Atrial Fibrillation23) 
A post hoc analysis was conducted with 2782 subjects (15%) from 
10 Asian countries and 15331 subjects from 34 other countries, for 
a total study population of 18113 subjects in the RE-LY clinical tri-
al, to compare the incidence of cerebral hemorrhage and severe 
bleeding according to dabigatran or warfarin therapy. In the Asian 
population, the incidence of cerebral hemorrhage was significantly 
Table 3. The recommendation of the Korean Heart Rhythm Society for patients with nonvalvular AF (continued)
  8-4.  For patients with CrCl ≥30mL/min, apixaban should be ceased 1 day prior to procedures with low bleeding risk, and 2 days prior to procedure with  
 high bleeding risk. For patients with <30 mL/min, apixaban should be ceased 2 days prior to procedures with low bleeding risk, and more than  
 2 days prior to procedures with high bleeding risk.
9.  Anticoagulation therapy for conducting an elective cardioversion or radiofrequency catheter ablation
  9-1.  To conduct elective direct current cardioversion for patients with AF of ≥48 hours duration or unknown time of occurrence, anticoagulant therapy  
 with warfarin (INR 2.0–3.0) is recommended for ≥3 weeks prior to and ≥4 weeks after cardioversion to reduce the risk of thromboembolism. 
  9-2.  To conduct radiofrequency catheter ablation for patients with AF of ≥48 hours duration or unknown time of occurrence, anticoagulant therapy  
 with warfarin (INR 2.0–3.0) is recommended for ≥3 weeks prior to and 2 months after cardioversion to reduce the risk of thromboembolism. 
  9-3. For the application of NOACs prior to or after elective cardioversion, supporting evidence is currently insufficient and limited. 
10. For patients with atrial flutter, antithrombotic therapy is recommended according to the same criteria applied for AF.
AF: atrial fibrillation, NOACs: novel oral anticoagulants, INR: international normalized ratio, TIA: transient ischemic attack
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lower in both the dabigatran 110 mg (D110) and 150 mg (D150) groups 
than in the warfarin group (D110 versus warfarin HR, 0.15; 95% CI, 
0.03–0.66 and D150 versus warfarin HR, 0.22; 95% CI, 0.06–0.77). 
Severe bleeding was also lower in both D110 and D150 groups com-
pared to the warfarin group (D110 2.22% per year, D150 2.17% per 
year, and warfarin 3.82% per year). In the non-Asian population, there 
was no difference in the incidence of cerebral hemorrhage or se-
vere bleeding.
Apixaban versus Warfarin: subgroup analysis on ARISTOTLE 
trial7) 
There is no report published so far analyzing the incidence of 
bleeding complication in the Asian population according to the use 
of apixaban or warfarin. But from the results of subgroup analysis 
in the ARISTOTLE trial, the incidence of severe bleeding in the Asian 
population was lower in the apixaban group than in the warfarin 
group.
 
Rivaroxaban for stroke prevention in East Asian patients 
from the ROCKET atrial fibrillation trial24)
A total of 932 (6.5%) ROCKET AF participants resided in East Asia. 
Despite higher absolute event rates for efficacy and safety outcomes 
in East Asians, the relative efficacy of rivaroxaban versus warfarin 
with respect to the primary efficacy end point (stroke/systemic em-
bolism) was consistent among East Asians and non-East Asians (in-
teraction p=0.666). Relative event rates for major or nonmajor clini-
cally relevant bleeding in patients treated with rivaroxaban and 
warfarin were consistent among East Asians and non-East Asians 
(interaction p=0.867). Observed relative efficacy and safety of riva-
roxaban versus warfarin were similar in patients within and outside 
East Asia.
Nonwhite patients receiving warfarin had a significantly higher 
risk of ICH compared with whites, presenting a HR of 2.05 for blacks, 
2.06 for Hispanics, and 4.1 for Asians. There was no difference in 
the incidence of ICH among racial groups not receiving warfarin.25) 
Because the prevalence of hemorrhagic stroke is about 2.4 times 
higher in Asians than in other ethnic groups, the optimal INR rage in 
Fig. 1. The algorithm of antithrombotic therapy for patients with nonvalvular atrial fibirillation. *Aspirin, clopidogrel or both. Solid-line box: recommended 
option, dotted-line box: alternative option. NOACs: new oral anticoagulants, VKA: vitamin K antagonist. 
No  
antithrombotic
therapy
NOACs
No
Yes
Bleeding Risk Assessment
(HAS-BLED score)
Consider patient clinical status
and preferences
Oral anticoagulant therapy 
(OAC)
<65 years and lone AF
(including females)
Nonvalvular AF
Atrial fibrillation (AF)
Valvular AF
VKA (warfarin)
Patients with nonvalvular AF and CHA2DS2-VASc score of 1:  
no antithrombotic therapy or antiplatelet therapy* may be considered
10 ≥2
Stroke Risk Assessment
(CHA2DS2-VASc score)
18 The Korean Heart Rhythm Society’s 2014 Statement on Antithrombotic Therapy
http://dx.doi.org/10.4070/kcj.2015.45.1.9 www.e-kcj.org
Asians was recommended as INR 1.6–2.6 for patients over 70 years 
in the APHRS 2013 guideline. The recently published meta-analysis 
data for all four NOACs, using data collected during the pivotal 
phase 3 clinical trials for stroke prevention and bleeding complica-
tion, presented a favorable risk-benefit profile with significant re-
duction in stroke, ICH, and mortality, with similar major bleeding 
as for warfarin.16) Hence, with respect to ICH (including hemorrhagic 
stroke), NOACs can be very beneficial for Asian patients with non-
valvular AF, although additional supporting study results are re-
quired. 
Conclusion
Antithrombotic therapy plays a very important role in prevent-
ing stroke and systemic thromboembolism in patients with nonva-
vular AF. However, the clinical characteristics of each patient should 
be carefully considered to maximize the preventative effect and 
minimize bleeding complications from the drug. The CHA2DS2-VASc 
score is recommended over the CHADS2 score for assessment of 
stroke risk. To quantify bleeding risk, the HAS-BLED score is recom-
mended. For patients with nonvalvualr AF and a CHA2DS2-VASc 
score of 0, antithrombotic therapy is not recommended. OAC ther-
apy is recommended when the CHA2DS2-VASc score is 2 or greater. 
NOACs should be considered rather than warfarin if there is a pos-
sibility of bleeding complications and based upon the results of past 
studies. For patients with nonvalvualr AF and a CHA2DS2-VASc score 
of 1, OAC therapy is preferred, but no antithrombotic therapy or 
treatment with antiplatelet agents can be also considered (Fig. 1).
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